Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Vinorelbine, and Filgrastim in HER-2 Negative Stage IV Breast Cancer
NCT00015938Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2001
- Primary completion
- Feb 2005
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, vinorelbine and filgrastim in breast cancer, sponsored by SWOG Cancer Research Network. Primary endpoints: 1-year survival, Response Rate and 2 more. Started May 2001; status: completed.
02
Drugs
docetaxelvinorelbinefilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00015938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015938.